Quantcast

Latest NovoCure Stories

2014-12-02 08:31:14

Based on the results of the trial's pre-specified interim analysis all control patients in the EF-14 phase III trial will be offered the opportunity to cross over to receive Tumor Treating Fields

2014-12-01 08:30:21

Planned interim analysis demonstrates the EF-14 Phase III trial met its endpoints of progression-free survival and overall survival ST. HELIER, Jersey, Dec.

2014-11-15 12:21:23

Data presented today as a late-breaking abstract at the Society for Neuro-Oncology 2014 Annual Meeting in Miami demonstrated the EF-14 trial met its primary endpoint of progression-free survival and

2014-09-25 08:26:59

Analyses of PRiDe, a registry of 457 recurrent glioblastoma patients, show that patients treated with the NovoTTF(TM)-100A System at their first and second recurrences had median overall survivals

2014-05-08 12:29:01

#TuneIn2GBM Social Media Campaign to Raise Awareness to Help Fight a Deadly Form of Brain Cancer PORTSMOUTH, N.H., May 8, 2014 /PRNewswire/ -- For the second consecutive year, Novocure

2011-04-16 00:44:03

Novocure today announced that the U.S. Food and Drug Administration (FDA) approved the NovoTTF-100A System (NovoTTF) for the treatment of adult patients with glioblastoma multiforme (GBM) brain tumors, following tumor recurrence after receiving chemotherapy.

2011-03-17 18:24:00

WASHINGTON, March 17, 2011 /PRNewswire/ -- Novocure announced today that the U.S.


Word of the Day
swell-mobsman
  • A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.
Use of the word 'swell-mobsman' dates at least to the early 1800s.